The Study of Mesenchymal Stem Cells Treat Autoimmune Pulmonary Alveolar Proteinosis in Vitro

Launched by GUANGZHOU INSTITUTE OF RESPIRATORY DISEASE · Nov 28, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Sign an informed consent form before any research-related activities;
• • 2. No gender restrictions, age ≥18 years old, and ≤75 years old;
• 3. Patients who need to receive whole lung lavage due to the needs of the disease, and the patient agrees to perform whole lung lavage. The standards are as follows:
• • 1. The diagnosis of aPAP is clear, and the anti-GM-CSF antibody in serum is greater than 5 μg/ml;
• • 2. PaO2 \<65 mmHg;
• • 3. P(A-a)O2\>40 mmHg;
• • 4. Intrapulmonary shunt \>10%-12%.
• Exclusion Criteria:
• • 1. Suffering from multiple chronic respiratory diseases at the same time, including but not limited to chronic obstructive pulmonary disease, pulmonary fibrosis, and asthma;
• • 2. Various malignant tumors or a history of malignant tumors;
• • 3. Uncontrolled pulmonary or systemic infection;
• • 4. Severe other systemic diseases: acute myocardial infarction, unstable angina pectoris, liver cirrhosis, acute glomerulonephritis, etc.;
• • 5. Syphilis, HIV, HCV antibody positive;
• • 6. Patients with coagulation disorders who cannot perform bronchoscopy, such as hemophilia, giant platelet syndrome, thrombocytopenia, etc.;
• • 7. Severe renal impairment, serum creatinine \> 1.5 times the upper limit of normal;
• • 8. Liver disease or liver function damage: ALT, AST, total bilirubin \> 2 times the upper limit of normal;
• • 9. Have any coexisting medical conditions or diseases that the investigators judge may impair the development of this trial;
• • 10. Social and mental disability, no legal capacity/limited capacity;
• • 11. Refuse to sign the informed consent.
• • -